*Camila Fernandez Zapata1,2, Ginevra Giacomello3, Eike J. Spruth2, Jinte Middeldorp4, Gerardina Gallacio1, Adeline Dehlinger1, Julia K. H. Leman8, Stephan Schlickeiser5, Desiree Kunkel5, Elly M Hol6, Friedemann Paul7, Maria K. Parr3, Josef Priller2,9, Chotima Böttcher1,2
(1. ECRC, Max Delbrueck Center for Molecular Medicine and Charité – Univ, Berlin, Germany, 2. Dept of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité – Univ, Berlin, Germany, 3. Inst of Pharmacy, Freie Univ Berlin, Berlin, Germany, 4. Dept of Immunobiology, Biomedical Primate Research Center, Rijswijk, The Netherlands, 5. Inst of Medical Immunology and Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité – Univ, Berlin, Germany, 6. Dept of Translational Neuroscience, Univ Medical Center Utrecht Brain Center, Utrecht Univ, The Netherlands, 7. NeuroCure Clinical Research Center, Charité - Univ, Berlin, Germany, 8. Inst for biology, Humboldt Univ, Berlin, Germany, 9. Clinic and Polyclinic for Psychiatry and Psychotherapy, Technic Univ Munich, Munich, Germany.)
キーワード:Neurodegeneration, Myeloid cells, Mass Cytometry, Immune profiling
抄録パスワード認証
抄録本文の閲覧にはパスワードが必要です。以下のパスワードをご入力の上、ご利用ください。
PW: Neuro2022